Can you compare four BTK inhibitors—ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib—in adult patients with malignancies?

Indirect or limited evidence suggests varied safety and efficacy profiles among ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib, but direct comparative studies are lacking. Clinical decisions should consider specific patient risk factors, especially cardiovascular safety.